Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

Journal of Hepatology

Volumn 62, Issue 3, 2015, Pages 701-711

  Miro, Jose M ^a   Stock, Peter ^b   Teicher, Elina ^c   Duclos Vallée, Jean Charles ^d   Terrault, Norah ^e   Rimola, Antoni ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BICÊTRE HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Coinfection; DAA; Direct antiviral agents; HCV; Hepatocellular carcinoma; HIV; Liver retransplantation; Liver transplantation; Pegylated interferon; Ribavirin; Simeprevir; Sofosbuvir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PROTOCOL; DONOR SELECTION; DRUG TOLERABILITY; GRAFT RECIPIENT; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER GRAFT; MIXED INFECTION; MORTALITY; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT REFERRAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; RECURRENT DISEASE; RETRANSPLANTATION; RISK ASSESSMENT; SURGICAL RISK; SURVIVAL RATE; TREATMENT RESPONSE; COINFECTION; COMPLICATION; HIV INFECTIONS; LIVER TRANSPLANTATION; PATIENT SELECTION; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DONOR SELECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84922986893     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.032     Document Type: Review

References (57)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet 372 2008 293 299
2. E. Martinez, A. Milinkovic, E. Buira, E. de Lazzari, A. Leon, and M. Larrousse Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area HIV Med 8 2007 251 258
3. A.N. Fox, P.A. Vagefi, and P.G. Stock Liver transplantation in HIV patients Semin Liver Dis 32 2012 177 185
4. J.M. Miro, M. Laguno, A. Moreno, and A. Rimola Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 44 2006 S140 S145
5. M. Tateo, A.M. Roque-Afonso, T.M. Antonini, F. Medja, A. Lombes, and C. Jardel Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity AIDS 23 2009 1069 1076
6. C.S. Coffin, P.G. Stock, L.M. Dove, C.L. Berg, N.N. Nissen, and M.P. Curry Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients Am J Transplant 10 2010 1268 1275
7. M.E. de Vera, I. Dvorchik, K. Tom, B. Eghtesad, N. Thai, and O. Shakil Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C Am J Transplant 6 2006 2983 2993
8. J.C. Duclos-Vallee, C. Feray, M. Sebagh, E. Teicher, A.M. Roque-Afonso, and B. Roche Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 47 2008 407 417
9. J.M. Miro, M. Montejo, L. Castells, A. Rafecas, S. Moreno, and F. Aguero Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study Am J Transplant 12 2012 1866 1876
10. N.A. Terrault, M.E. Roland, T. Schiano, L. Dove, M.T. Wong, and F. Poordad Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection Liver Transpl 18 2012 716 726
11. M.A. Kish Guide to development of practice guidelines Clin Infect Dis 32 2001 851 854
12. J.A. Pineda, M. Romero-Gomez, F. Diaz-Garcia, J.A. Giron-Gonzalez, J.L. Montero, and J. Torre-Cisneros HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis Hepatology 41 2005 779 789
13. J.M. Miro, J. Torre-Cisnero, A. Moreno, M. Tuset, C. Quereda, and M. Laguno GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005) Enferm Infecc Microbiol Clin 23 2005 353 362
14. P.A. Grossi Update in HIV infection in organ transplantation Curr Opin Organ Transplant 17 2012 586 593
15. J. O'Grady, C. Taylor, and G. Brook Guidelines for liver transplantation in patients with HIV infection (2005) HIV Med 6 2005 149 153
16. A. Subramanian, M. Sulkowski, B. Barin, D. Stablein, M. Curry, and N. Nissen MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates Gastroenterology 138 2010 159 164
17. C. Cooper, S. Kanters, M. Klein, P. Chaudhury, P. Marotta, and P. Wong Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort AIDS 25 2011 1
18. J.C. Duclos-Vallee, M. Tateo, E. Teicher, A.M. Roque-Afonso, T.M. Antonini, and A. Coilly Results of liver transplantation in a large cohort of more than 100 HIV infected patients - a monocentric experience Liver Transpl 6 2011 S80
19. M.V. Ragni, S.H. Belle, K. Im, G. Neff, M. Roland, and P. Stock Survival of human immunodeficiency virus-infected liver transplant recipients J Infect Dis 188 2003 1412 1420
20. J.C. Duclos-Vallee, D. Vittecoq, E. Teicher, C. Feray, A.M. Roque-Afonso, and A. Lombes Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients J Hepatol 42 2005 341 349
21. A. Samri, A.M. Roque-Afonso, O. Beran, M. Tateo, E. Teicher, and C. Feray Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial) J Hepatol 51 2009 1000 1009
22. D. Samuel, and J.C. Duclos-Vallee Liver transplantation in the human immunodeficiency virus-hepatitis C virus coinfected patient: time to sum up Hepatology 57 2013 409 411
23. T.M. Antonini, M. Sebagh, A.M. Roque-Afonso, E. Teicher, B. Roche, and R. Sobesky Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation Am J Transplant 11 2011 1686 1695
24. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
25. N. Terrault, K.R. Reddy, F. Poordad, M. Curry, T. Schiano, and J. Johl Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients Am J Transplant 14 2014 1129 1135
26. L. Castells, A. Rimola, C. Manzardo, A. Valdivieso, J.L. Montero, and R. Barcena Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study J Hepatol 62 1 2015 92 100
27. Sulkowski M, Rodriguez-Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). In: 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, November 1-5, 2013. Abstract212.
28. M. Charlton, E. Gane, M.P. Manns, M.P. Curry, R.S. Brown, and P.Y. Kwo Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterol 148 2015 108 117
29. Forns X, Prieto M, Charlton M, McHutchinson J, Symonds W, Brainard D. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. In: The 49th Annual Meeting of the European Association for the Study of the Liver; 2014; London, England.
30. A.M. Pellicelli, M. Montalbano, R. Lionetti, C. Durand, P. Ferenci, and G. D'Offizi Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late Dig Liver Dis 46 2014 923 927
31. Antonini T, Coilly A, Samuel D, Haim-Boukobza S, Duclos-Vallee JC, Sebagh M. Triple anti-viral C therapy with Boceprevir or Telaprevir in HIV/HCV coinfected patients after liver transplantation. In: The Liver Meeting: 64th Annual Meeting of the American Association for the Study of Liver Disease. November 2013, Washington, USA. Abstract 1959.
32. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, and A. Corregidor Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
33. Curry M, Forns X, Chung R, Terrault N, Brown RS, Jr., Fenkel J. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. In: The 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2014; Brisbane, Australia.
34. A. Moreno, C. Cervera, J. Fortun, M. Blanes, E. Montejo, and M. Abradelo Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A FIPSE/GESIDA Prospective Cohort Study Liver Transpl 18 2012 70 81
35. J. Harbell, J. Fung, N. Nissen, K. Olthoff, S.S. Florman, and D.W. Hanto Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients Surgery 152 2012 376 381
36. P.T. Cherian, W. Alrabih, A. Douiri, A. Quaglia, M.A. Heneghan, and J. O'Grady Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required? Liver Transpl 18 2012 82 88
37. Aguero F, Herrero JI, Manzardo C, Valdivieso A, Abradelo M, Salcedo M et al. Incidence of de novo tumors in HIV-infected liver transplant recipients: a multicenter study. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Barcelona, Spain. 10 - 13 May 2014
38. L. Tricot, E. Teicher, G. Peytavin, D. Zucman, F. Conti, and Y. Calmus Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs Am J Transplant 9 2009 1946 1952
39. A. Moreno, M.J. Perez-Elias, J.L. Casado, J. Fortun, R. Barcena, and C. Quereda Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation Liver Transpl 16 2010 530 532
40. M.A. Thompson, J.A. Aberg, J.F. Hoy, A. Telenti, C. Benson, and P. Cahn Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel JAMA 308 2012 387 402
41. Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus Enferm Infecc Microbiol Clin 31 2013 604 613
42. C.T. de Kanter, M.I. Blonk, A.P. Colbers, B.J. Schouwenberg, and D.M. Burger Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir Clin Infect Dis 56 2013 300 306
43. L. Frassetto, L. Floren, B. Barin, M. Browne, A. Wolfe, and M. Roland Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients Biopharm Drug Dispos 34 2013 442 451
44. E.G. Hulskotte, H.P. Feng, F. Xuan, M.G. van Zutven, M.A. Treitel, and E.A. Hughes Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir Clin Infect Dis 56 2013 718 726
45. R.P. van Heeswijk, M. Beumont, R.S. Kauffman, and V. Garg Review of drug interactions with telaprevir and antiretrovirals Antivir Ther 18 2013 553 560
46. J.J. Kiser, and J.R. Burton Jr. Everson GT: drug-drug interactions during antiviral therapy for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 596 606
47. D.E. Karageorgopoulos, O. El-Sherif, S. Bhagani, and S.H. Khoo Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection Curr Opin Infect Dis 27 2014 36 45
48. th, 2014].
49. Back D, Gibbons S. The University of Liverpool HIV drug interactions website. Available at: < www.hiv-druginteractions.org >. [Accessed October 5th, 2014].
50. E. Vibert, J.C. Duclos-Vallee, M.R. Ghigna, E. Hoti, C. Salloum, and C. Guettier Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection Hepatology 53 2011 475 482
51. B.F. Di, G. Tarantino, G. Ercolani, U. Baccarani, R. Montalti, and R.N. De Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients Oncologist 18 2013 592 599
52. F. Di Benedetto, N. De Ruvo, M. Berretta, M. Masetti, R. Montalti, and S. Di Sandro Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era J Clin Oncol 24 2006 e26 e27
53. F. Di Benedetto, N. De Ruvo, M. Berretta, M. Masetti, R. Montalti, and S. Di Sandro Hepatocellular carcinoma in HIV patients treated by liver transplantation Eur J Surg Oncol 34 2008 422 427
54. M. Berretta, E. Garlassi, B. Cacopardo, A. Cappellani, G. Guaraldi, and S. Cocchi Hepatocellular carcinoma in HIV-infected patients: check early, treat hard Oncologist 16 2011 1258 1269
55. Agüero FH, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, et al. HIV infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Conference on Retroviruses and Opportunistic Infections (CROI 2015), February 23 to February 26, 2015, Seattle (Washington, USA). Abstract 2097389.
56. M. Gastaca, A. Valdivieso, M. Montejo, J. Bustamante, and J.O. de Urbina Is antithrombotic prophylaxis required after liver transplantation in HIV-infected recipients? Am J Transplant 12 2012 2258
57. Miro JM, Aguero F, Stock P, Grossi P, Agarwal K. Liver retransplantation in HIV-infected patients: a multicenter and multinational cohort study. Conference on Retroviruses and Opportunistic Infections (CROI 2013) March 3-6, 2013, Atlanta (Georgia, USA). Abstract P-141. 2014.